Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Nguyen, Andrew H., Elliott, Irmina A., Wu, Nanping, Matsumura, Cynthia, Vogelauer, Maria, Attar, Narsis, Dann, Amanda, Ghukasyan, Razmik, Toste, Paul A., Patel, Sanjeet G., Williams, Jennifer L., Li, Luyi, Dawson, David W., Radu, Caius, Kurdistani, Siavash K., Donahue, Timothy R.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386671/
https://ncbi.nlm.nih.gov/pubmed/27894105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados